Press-release for stocks in the wholesale trade sector related to vitargus

Prices are updated after-hours

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K

| -5.71% | O: 33.81% H: 3.2% C: -8.9%
vitargus biopharma royalties global deal

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
Published: 2023-08-03 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K

| -67.22% | O: -1.32% H: 5.37% C: 3.36%
vitargus approval

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
Published: 2023-05-22 (Crawled : 12:20) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K

| 35.69% | O: -0.44% H: 0.0% C: -5.0%
vitargus australia approval hospital biopharma eye study

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand
Published: 2023-04-06 (Crawled : 13:20) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K

| 58.65% | O: 0.0% H: 4.13% C: 3.83%
vitargus update biopharma

| 65.0% | O: 7.02% H: 7.46% C: 1.21%
vitargus update biopharma

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K

| 36.55% | O: 3.45% H: 10.33% C: 2.67%
vitargus biopharma approval tga study

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K

| 26.92% | O: 1.28% H: 0.0% C: -2.53%
vitargus fda biopharma approval update study

ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
Published: 2022-10-05 (Crawled : 16:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K

| 13.87% | O: 2.07% H: 5.92% C: 2.22%
vitargus biopharma australia approved study

ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
Published: 2022-09-09 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K

| -13.16% | O: -0.88% H: 1.77% C: -2.65%
vitargus biopharma study

ABVC BioPharma Provides Vitargus® Update
Published: 2022-08-18 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K

| 31.58% | O: 4.08% H: 18.76% C: 14.93%
vitargus biopharma update

ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
Published: 2022-06-16 (Crawled : 13:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K

| -3.88% | O: -4.85% H: 4.08% C: -1.86%
vitargus biopharma australia

ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
Published: 2022-04-26 (Crawled : 18:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K

| -57.87% | O: 0.0% H: 0.43% C: -4.68%
biopharma vitargus

ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites
Published: 2022-01-05 (Crawled : 14:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K